An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
University of Wisconsin, Madison
Summary
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
Description
This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+) * Adults who received a kidney transplant, liver transplant, or any combination thereof Exclusion Criteria: * Known contraindication to letermovir or its excipients * Current participation in another CMV related study * Unwilling or unable to participate in the study protocol
Interventions
- DrugLetermovir
1 tablet by mouth, once daily, for 84 days
Location
- University of Wisconsin - MadisonMadison, Wisconsin